IFN-γ activation of mesenchymal stem cells for treatment and prevention of graft versus host disease

被引:485
作者
Polchert, David [1 ]
Sobinsky, Justin [1 ]
Douglas, G. W. [1 ]
Kidd, Martha [1 ]
Moadsiri, Ada [1 ]
Reina, Eduardo [1 ]
Genrich, Kristyn [1 ]
Mehrotra, Swati [2 ]
Setty, Suman [2 ]
Smith, Brett [3 ]
Bartholomew, Amelia [1 ]
机构
[1] Univ Illinois, Dept Surg, Chicago, IL 60680 USA
[2] Univ Illinois, Dept Pathol, Chicago, IL 60680 USA
[3] Univ Illinois, Dept Radiat Oncol, Chicago, IL 60680 USA
关键词
mesenchymal stem cell; GVH disease; IFN-gamma;
D O I
10.1002/eji.200738129
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Graft versus host disease (GVHD), mediated by donor T cells, is a significant source of morbidity and mortality following allogeneic stem cell transplantation. Mesenchymal stem cells (MSC) can successfully treat ongoing graft versus host disease, presumably due to their ability to suppress donor T cell proliferation. Little is known about the potential of MSC to prevent GVHD. Here we show that bone marrow-isolated MSC can suppress the development of GVHD if given after donor T cell recognition of antigen. IFN-gamma was required to initiate MSC efficacy. Recipients of IFN-gamma(-/-) T cells did not respond to MSC treatment and succumbed to GVHD. MSC, pre-treated with IFN-gamma, became immediately active and could suppress GVHD more efficiently than a fivefold-greater number of MSC that were not activated. When given at the time of bone marrow transplantation, activated MSC could prevent GVHD mortality (100% survival, p=0.006). MSC activation was dependent on the magnitude of IFN-gamma exposure, with increased IFN-gamma exposure leading to increased MSC suppression of GVHD. Activated MSC present a new strategy for preventing GVHD using fewer MSC.
引用
收藏
页码:1745 / 1755
页数:11
相关论文
共 68 条
[1]   Human mesenchymal stem cells modulate allogeneic immune cell responses [J].
Aggarwal, S ;
Pittenger, MF .
BLOOD, 2005, 105 (04) :1815-1822
[2]   Improving immune reconstitution while preventing GvHD in allogeneic stem cell transplantation [J].
André-Schmutz, I ;
Dal Cortivo, L ;
Fischer, A ;
Cavazzana-Calvo, M .
CYTOTHERAPY, 2005, 7 (02) :102-108
[3]   Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation:: a phase 1/2 study [J].
André-Schmutz, I ;
Le Deist, F ;
Hacein-Bey-Abina, S ;
Vitetta, E ;
Schindler, J ;
Chedeville, G ;
Vilmer, E ;
Fischer, A ;
Cavazzana-Calvo, M .
LANCET, 2002, 360 (9327) :130-137
[4]   Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies:: report of the European experience 1968-99 [J].
Antoine, C ;
Müller, S ;
Cant, A ;
Cavazzana-Calvo, M ;
Veys, P ;
Vossen, J ;
Fasth, A ;
Heilmann, C ;
Wulffraat, N ;
Seger, R ;
Blanche, S ;
Friedrich, W ;
Abinun, M ;
Davies, G ;
Bredius, R ;
Schulz, A ;
Landais, P ;
Fischer, A .
LANCET, 2003, 361 (9357) :553-560
[5]   Management of acute graft versus host disease (GvHD) [J].
Bacigalupo, A ;
Palandri, F .
HEMATOLOGY JOURNAL, 2004, 5 (03) :189-196
[6]   Management of acute graft-versus-host disease [J].
Bacigalupo, Andrea .
BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 (02) :87-98
[7]   Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection [J].
Baddoo, M ;
Hill, K ;
Wilkinson, R ;
Gaupp, D ;
Hughes, C ;
Kopen, GC ;
Phinney, DG .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 89 (06) :1235-1249
[8]   Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo [J].
Bartholomew, A ;
Sturgeon, C ;
Siatskas, M ;
Ferrer, K ;
McIntosh, K ;
Patil, S ;
Hardy, W ;
Devine, S ;
Ucker, D ;
Deans, R ;
Moseley, A ;
Hoffman, R .
EXPERIMENTAL HEMATOLOGY, 2002, 30 (01) :42-48
[9]   Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation [J].
Baud, O ;
Goulet, O ;
Canioni, D ;
Le Deist, F ;
Radford, I ;
Rieu, D ;
Dupuis-Girod, S ;
Cerf-Bensussan, N ;
Cavazzana-Calvo, M ;
Brousse, N ;
Fischer, A ;
Casanova, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (23) :1758-1762
[10]   Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness [J].
Beyth, S ;
Borovsky, Z ;
Mevorach, D ;
Liebergall, M ;
Gazit, Z ;
Aslan, H ;
Galun, E ;
Rachmilewitz, J .
BLOOD, 2005, 105 (05) :2214-2219